LUNG (Pulmonx) LT-Debt-to-Total-Asset: 0.46 (As of Mar. 2026)

Pulmonx LUNG -5.44% 49 LT-Debt-to-Total-Asset is 0.46 as of Mar. 2026. GuruFocus rates LUNG with a GF Score™ of 49/100 and a GF Value™ of $7.13 (Possible Value Trap). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pulmonx's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.46.

Pulmonx's long-term debt to total assets ratio increased from Mar. 2025 (0.32) to Mar. 2026 (0.46). It may suggest that Pulmonx is progressively becoming more dependent on debt to grow their business.

Pulmonx (NAS:LUNG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pulmonx LT-Debt-to-Total-Asset Related Terms

Pulmonx LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Pulmonx's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmonx LT-Debt-to-Total-Asset Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.10

0.11

0.20

0.32

0.43

Pulmonx Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.32	0.38	0.40	0.43	0.46

49GF Score

Pulmonx Corp LUNG

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pulmonx LT-Debt-to-Total-Asset Calculation

Pulmonx's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	55.048	/	129.291
	=	0.43

Pulmonx's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	54.95	/	119.966
	=	0.46

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.46 mean?

Pulmonx (LUNG) has a LT-Debt-to-Total-Asset of 0.46 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pulmonx and its competitors.

Is Pulmonx's LT-Debt-to-Total-Asset too high?

Pulmonx's current LT-Debt-to-Total-Asset is 0.46. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Pulmonx's LT-Debt-to-Total-Asset compare to MDAI and QTI?

Pulmonx's LT-Debt-to-Total-Asset of 0.46 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pulmonx and its competitors. Pulmonx's current LT-Debt-to-Total-Asset is 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pulmonx stock overvalued right now?

Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.39 — trading 80.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.46. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Pulmonx (LUNG), the current LT-Debt-to-Total-Asset is 0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulmonx (LUNG) Overvalued in 2026?

Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued. The current stock price of $1.39 is trading 80.5% below its estimated GF Value™ of $7.13. GuruFocus considers Pulmonx to be Possible Value Trap.

Key valuation signals for LUNG:

LT-Debt-to-Total-Asset: 0.46
GF Value™: $7.13 vs. price of $1.39 (80.5% below fair value)
GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pulmonx Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies MDAI QTI COCH XTNT SRTS POSC NSYS ECOR ELUT SERA ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges 4NI:Germany

Address 700 Chesapeake Drive, Redwood, CA, USA, 94063

Website https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

49GF Score

Get the complete analysis for LUNG

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39

Price

$7.13

GF Value

View LUNG Analysis

See LT-Debt-to-Total-Asset data for all stocks →